ABSTRACT

Objective. C-reactive protein (CRP) and homocysteine are markers of cardiovascular risk that may have inflammatory effects. HMG coenzyme A reductase inhibitors (statins) have anti-inflammatory effects in vitro, but it is not clear if such responses in vivo are secondary to lipid lowering. We examined the hypothesis that CRP and homocysteine would stimulate cytokine release in human whole blood and that short-term treatment with a statin would inhibit it.

Methods. The time course of IL-6 and MCP-1 production was determined in whole blood incubated with saline, 1 μg/mL lipopolysaccharide (LPS), 50 and 100 μM/L DL-homocysteine, and 5 μg/mL human recombinant CRP for 24 hours at 37°C under 5% CO2 atmosphere. Cytokine responses were determined in blood drawn from 15 healthy volunteers before and after administration of pravastatin 40 mg daily for 2 days.

Results. Both human recombinant CRP and LPS significantly increased the production of IL-6 and MCP-1 in whole blood samples more than 4-fold (P < 0.001) but homocysteine did not. Oral administration of pravastatin, 40 mg daily for 2 days, decreased CRP-stimulated IL-6 production by approximately 20% (P = 0.02) 6 hours after incubation, but did not affect MCP-1 production (P = 0.69). Pravastatin treatment did not affect LPS-stimulated MCP-1 but increased IL-6 modestly.

Conclusions. CRP stimulated the production of the proatherogenic mediators MCP-1 and IL-6 in human whole blood, but homocysteine did not. CRP-stimulated production of IL-6, but not MCP-1, was modestly attenuated by short-term treatment with pravastatin.

Key Words. Pravastatin; C-reactive protein; Interleukin-6

Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://www3.interscience.wiley.com/authorresources/onlineopen.html
release of adhesion molecules, MCP-1 and IL-6 in human endothelial cells [8]. Thus, homocysteine and CRP appear to act not only as markers of cardiovascular risk, but based on in vitro studies, to induce inflammatory responses and thus perhaps play a direct role in the pathogenesis of atherosclerosis. However, whether these pro-inflammatory effects of CRP and homocysteine occur in vivo is not clear.

Drugs that inhibit hydroxymethyl glutaryl (HMG) coenzyme A reductase activity (statins) decrease the production of low-density lipoprotein (LDL) cholesterol and up-regulate the expression of LDL-receptors [9]. Statins reduce cardiovascular mortality, but appear to do so to a greater extent than would be predicted from the LDL cholesterol reduction achieved [10]. Accordingly, other mechanisms have been sought through which statins may decrease cardiovascular risk. Anti-oxidant, antiproliferative, immunomodulatory and anti-inflammatory effects have been identified in vitro and as a result the effects of statins have been described as pleiotropic [11]. However, little is known about the in vivo anti-inflammatory effects of statins and whether these are independent of cholesterol lowering.

Treatment with statins consistently decreases plasma CRP concentrations [12,13]. Statins also reduce the serum levels and the expression of proinflammatory cytokines and chemokines in leukocytes from treated hypercholesterolemic patients [14]. However, the effects of statins on CRP and cytokines in vivo have been studied after several weeks of treatment when effects on cholesterol have already occurred, and thus anti-inflammatory effects may be secondary to lower cholesterol concentrations. We postulated that if statins have a direct anti-inflammatory effect in vivo this effect would occur rapidly, as it does in vitro.

First, we examined the hypothesis that CRP and homocysteine would stimulate the production of IL-6 and MCP-1, proatherogenic cytokines, in whole blood and second, that this effect would be attenuated by short-term treatment with a statin. For at least 7 days and no alcohol or caffeine for at least 2 days before the study. The subjects had an average (±SEM) age of 27 ± 1 years and weight of 73.1 ± 3.6 kg. Subjects were fasted overnight and venous blood (50 mL) was drawn. Subjects then swallowed pravastatin 40 mg with water in the presence of an investigator. Twenty-four hours later subjects received a second 40 mg dose, again in the presence of an investigator, and 1.5 hours later, a time when peak concentrations of pravastatin are expected to occur, 50 mL blood was drawn. Several studies have shown that the mean time to reach maximum concentration of pravastatin is approximately 1.5 hours (range, 0.5–4 hours) [15], thus we drew blood for the ex vivo studies 1.5 hours after administration of pravastatin.

Venous blood from these volunteers was collected into tubes containing heparin, maintained at 37°C, and studied within 60 minutes. Cytokine production ex vivo was measured as previously described by ourselves and others [16,17]. Eight hundred µl of heparinized whole blood was incubated with 200 µL saline (control), lipopolysaccharide (LPS, Escherichia coli O111:B4 from Sigma, St. Louis, MO) (final concentration 1 µg/mL, n = 15), human recombinant CRP (Calbiochem, San Diego, CA) (final concentration 5 µg/mL, n = 15) or DL-homocysteine (Sigma, St Louis, MO) (final concentration 50 µM/L, n = 8, and 100 µM/L, n = 6) for 24 hours at 37°C under 5% CO2 atmosphere. At 0, 6, 10 and 24 hours samples were centrifuged in an Eppendorf microcentrifuge at 1,500 × g for 10 minutes. Supernatants were stored at −70°C until IL-6 and MCP-1 concentrations were measured. The 6-hour time-point was of primary interest as regards the effects of pravastatin because this was the shortest incubation period that we had shown in pilot studies resulted in a robust stimulation of cytokines by CRP. The experiments to determine the effects of homocysteine on cytokine production were discontinued when it became clear after studying 7 subjects that there was no effect.

**Methods**

The study was approved by the Institutional Review Board of Vanderbilt University Hospital and all subjects gave written informed consent.

We studied 15 healthy subjects (6 male and 9 female; 6 Caucasian, 5 African American, 3 Asian and 1 Hispanic) who had not taken any medica-
calculated by subtracting the concentrations in the saline controls from those induced by LPS or CRP.

Pravastatin concentrations were measured by HPLC. A 100 mg C<sub>18</sub> preparatory solid-phase extraction column (Sep-Pak Vac, Waters, Mississauga, ON) was initially washed with 1ml volumes of isopropyl alcohol, methanol and water. An aliquot (1000 µL) of plasma was added and the column was washed three times with 1ml of acetic acid: methanol: water (2:10:88 v/v) and then three times with 1 ml of ammonium hydroxide: methanol: water (2:10:88 v/v). The sample was eluted with 1ml methanol containing triethylamine (200 µL/100 mL) and it was evaporated to dryness at 40°C under a gentle stream of nitrogen. The residue was dissolved in an aliquot (100 µL) of HPLC mobile phase which consisted of acetonitrile: water (27.73 v/v) and triethylamine 500 µL/L at pH = 3.0 with phosphoric acid that also contained the internal standard, 5-methoxyypsoralen, (Indofine Chemical Company Inc., Somerville, NJ) at a concentration of 500 ng/mL. The solution was filtered (0.45 µm) and a sample (30 µL) was injected onto a 150 mm × 3.2 mm Prodigy C<sub>18</sub>, 5 mm column (Phenomenex, Torrance, CA) at a mobile flow rate of 0.4 mL/min. Absorbance detection at 238 nm was used to monitor the effluent. The retention times of pravastatin and 5-methoxyypsoralen were 13 and 23 minutes, respectively. The standard curve of pravastatin was linear over the range tested (0–200 ng/mL). The coefficient of variation was 3.3% at 25 ng/mL (n = 7) and the limit of detection was 5 ng/mL.

Measurement of Endotoxin Concentration
Recombinant human CRP contains low concentrations of endotoxin which were measured using a limulus amebocyte lysate assay (Cape Cod, Falmouth, MA) which has a lower limit of detection of 0.005 Endotoxin Units (EU).

Statistical Analysis
Results are expressed as mean ± SEM in the text and figures. Wilcoxon signed ranks tests were used to compare cytokine production in stimulated and in unstimulated whole blood and to compare stimulated IL-6 and MCP-1 production before and after the administration of pravastatin. Correlations were assessed by Spearman’s rank order test. Values of P < 0.05 were considered significant. Statistical analysis was performed with SPSS 11.5 for Windows (SPSS, Chicago, IL).

Results
Effects of CRP and DL-homocysteine on IL-6 and MCP-1 Production
The major findings of this study are that human recombinant CRP, but not homocysteine, stimulates cytokine production in human whole blood and that short-term treatment with a statin modestly inhibits CRP-stimulated IL-6 but not MCP-1 production after 6 hours of incubation.

LPS and recombinant CRP increased IL-6 (Figure 1a) and MCP-1 (Figure 1b) production significantly (all P values < 0.001 compared to saline control). This effect occurred rapidly, within 6 hours. Neither 50 nor 100 µM/L DL-homocysteine affected MCP-1 or IL-6 production significantly compared to saline (all P values > 0.07) (Figure 1a, b). Pravastatin reduced CRP-stimulated IL-6 production from 36.6 ± 4.3 ng/mL (median 34.1) to 27.4 ± 3.3 ng/mL (median 25.5), an average of −19.7% ± 8.3% after 6 hours of incubation (P = 0.02, Figure 2) but not after longer periods of incubation (Table 1). Pravastatin did not inhibit IL-6 production after 6 hours of incubation with LPS (55.1 ± 2.9 ng/mL compared to 51.4 ± 3.4 ng/mL before pravastatin, P = 0.09). IL-6 concentrations in LPS-stimulated whole blood for 10 hours tended to increase after subjects took pravastatin (P = 0.04, Table 1). Pravastatin did not affect CRP or LPS stimulated MCP-1 cytokine production (Table 2).

Plasma Pravastatin Concentrations
The mean plasma pravastatin concentration was 50.3 ± 9.7 ng/mL (range 5–159.6 ng/mL). There was no significant correlation between plasma pravastatin concentrations and percent change in CRP-stimulated IL-6 (r = -0.31, P = 0.27) or MCP-1 concentrations (r = 0.16, P = 0.56), or LPS-stimulated IL-6 (r = -0.49, P = 0.07) and MCP-1 concentrations (r = -0.15, P = 0.27). There was a weak negative correlation between pravastatin concentration and absolute reduction in IL-6 concentration (r = -2.329, P = 0.02).

Endotoxin Concentration
The average concentration of endotoxin in 5 µg/mL recombinant CRP (n = 4) was 0.38 ± 0.21 EU/mL and was >8 EU/mL in LPS 1 µg/mL, 100 ng/mL and 10 ng/mL, and 1.36 EU/mL in 1 ng/mL (n = 2, each).
Discussion

We found that human recombinant CRP stimulated production of the inflammatory cytokines IL-6 and MCP-1 in whole blood but that homocysteine did not. Short-term treatment with an HMG co-enzyme A reductase inhibitor, pravastatin, reduced IL-6 production modestly after stimulation by CRP and tended to increase IL-6 production after LPS.

Increasing evidence implicates CRP as a contributor to the pathogenesis of atherosclerosis. CRP accumulates in the macrophage rich areas of the atherosclerotic plaque [18] and increases the expression and release of macrophage derived pro-inflammatory cytokines such as interleukin-1β and IL-6 [19,20]. In endothelial cells, CRP increased the expression of vascular cell adhesion molecule (VCAM-1) and intracellular adhesion molecule (ICAM-1), and increased MCP-1 production and tissue factor release [8,21]. Based on in vitro and in vivo data we selected the concentration of CRP for study, 5 μg/mL. Thus, in patients with stable
or unstable angina, serum concentrations of CRP >3 μg/mL are associated with an increased risk of coronary events [22,23] and in vitro concentrations of 5 μg/mL had significant inflammatory effects [24].

We found that recombinant CRP markedly increased the production of IL-6 and MCP-1, cytokines that are thought to be important in the pathogenesis of atherosclerosis [25,26]. Human recombinant CRP is known to contain low concentrations of endotoxin. The question arises whether this could account for the ability of CRP to stimulate cytokine production. Various strategies, such as boiling CRP to destroy it and thus isolate the contribution of endotoxin to observed responses, or passing CRP through columns containing polymyxin to remove endotoxin, have been explored. However, low levels of endotoxin are present in apparently healthy subjects [27,28] and have been associated with risk of atherosclerosis [28]. Much higher levels of endotoxin (>50 pg/mL) are observed in subjects with chronic or recurrent bacterial infections, another risk factor for atherosclerosis [29]. Thus, considering the possibility that CRP and endotoxin are both risk factors for atherosclerosis and may act synergistically in vitro [20] and in vivo, our strategy was not to remove the endotoxin present in CRP but to measure the concentrations present. The concentrations of endotoxin present in CRP were low, generally less than 0.5 EU/mL, are unlikely to account for the cytokine stimulation by CRP [30]. Thus our studies suggest that human recombinant CRP in the presence of very low levels of endotoxin stimulates IL-6 and MCP-1 production in whole blood.

Treatment with a statin for several weeks has been shown to decrease CRP production [12] and to reduce the expression of IL-6, IL-8, and MCP-1 mRNA in peripheral blood cells and to decrease serum cytokine concentrations [31,32]. Statins have rapid anti-inflammatory effects in vitro decreasing the production of cytokines within hours [8,33,34]. Studies that have examined the

![Figure 2](image)

**Figure 2** Effect of pravastatin on IL-6 production in whole blood during stimulation with 5 g/mL recombinant CRP for 6 hours (n = 15). Administration of pravastatin reduced CRP-stimulated IL-6 production by an average of –20% (P = 0.02).

### Table 1 IL-6 production in recombinant CRP or LPS-stimulated whole blood before and after administration of pravastatin

| Incubation time | Before pravastatin | After pravastatin | P values |
|-----------------|--------------------|-------------------|----------|
| **Unstimulated (Saline)** | | | |
| 6 hours | 0.09 ± 0.05 | 0.10 ± 0.05 | 0.83 |
| 10 hours | 0.09 ± 0.05 | 0.13 ± 0.06 | 0.50 |
| 24 hours | 0.13 ± 0.06 | 0.16 ± 0.06 | 0.78 |
| **5 μg/mL CRP** | | | |
| 6 hours | 35.2 ± 17.5 | 25.5 ± 13.6 | 0.02 |
| 10 hours | 39.3 ± 3.27 | 33.6 ± 3.90 | 0.14 |
| 24 hours | 42.3 ± 3.28 | 40.6 ± 4.26 | 0.61 |
| **1 μg/mL LPS** | | | |
| 6 hours | 51.4 ± 3.4 | 55.1 ± 2.9 | 0.09 |
| 10 hours | 61.5 ± 4.69 | 69.9 ± 4.08 | 0.04 |
| 24 hours | 75.9 ± 20.1 | 80.7 ± 18.8 | 0.36 |

Values are mean SEM from 15 experiments performed in duplicates. The net production of IL-6 was calculated by subtracting the concentration without stimulus from those induced by LPS or recombinant CRP. Wilcoxon signed rank test was applied for statistical analysis.

*Asanuma et al.* Arch Drug Info 2008;1:14–22
effects of statins on cytokine production ex vivo have done so after several weeks of treatment [12] and thus have not separated out direct antiinflammatory effects from those due to the reduction in lipids and CRP [31]. Treatment with a statin decreases CRP and LDL cholesterol concentrations rapidly, with effects seen after 14 days [35]. However, treatment for 3 to 6 days does not alter LDL cholesterol concentrations [36] indicating that the effects noted in the present study after two doses are not likely to be secondary to lowering of cholesterol.

We chose to study pravastatin; there were several rationales for this choice. First, it is widely used clinically, and since it is not a CYP3A4 substrate has fewer interactions with other drugs. Second, an anti-inflammatory effect of pravastatin has been well demonstrated. Randomized, double-blind studies have shown that several statins decrease concentrations of C-reactive protein (CRP) and that the reductions obtained with different statins were similar [12]. However, the effect of pravastatin on CRP was independent of its lipid-lowering effects [13].

The finding that treatment with a statin has a rapid inhibitory effect on CRP stimulated IL-6 production is of interest, not only because it demonstrates a rapid anti-inflammatory action of a statin ex vivo, but also because IL-6 is thought to be one of the prime regulators of CRP production [37]. Furthermore, our findings suggest that CRP may stimulate IL-6. Concordant with this notion is the observation that CRP and IL-6 concentrations are correlated [38,39]. Thus the inhibitory effect of statins on CRP could be mediated in part by effects on IL-6.

The effects of pravastatin on CRP stimulated IL-6 production varied among individuals. Since pravastatin concentrations are known to vary more than 10-fold among individuals receiving the same dose [40], we examined the possible relationship between pravastatin concentrations and the change in cytokine production. There was no correlation between pravastatin concentrations and effect suggesting that variability in drug concentrations does not contribute substantially to the differences observed among individuals.

An inhibitory effect of pravastatin was observed on CRP-stimulated IL-6 after 6-hour incubation but not after longer incubation times. It is likely that multiple pathways of IL-6 activation are secondarily activated by the CRP-stimulated inflammation and that these may not be sensitive to pravastatin. Pravastatin did not affect either MCP-1 production and tended to increase LPS-stimulated IL-6 responses. The explanation for this is not clear but it suggests that the anti-inflammatory effects of statins may be specific to particular cytokines and stimuli.

The lack of effect of homocysteine on cytokine production was unexpected. Several lines of evidence suggest that hyperhomocysteinemia may be more than a marker of cardiovascular risk. Homocysteine is rapidly auto-oxidized resulting in the production of potent reactive oxygen species that result in damage to endothelial cells [41]. Homocysteine also limits the bioavailability of nitric oxide, and in cultured human aortic endothelial cells and THP-1 monocytes, decreases the expression and secretion of MCP-1 [7,38]. However, the effects of homocysteine on isolated cells in culture may not be representative of a more

| Table 2 | MCP-1 production in recombinant CRP or LPS-stimulated whole blood before and after administration of pravastatin |
|-----------------|-----------------|-----------------|
| Incubation time | MCP-1 concentration (pg/ml) | After pravastatin | P-values |
| Unstimulated (Saline) | | | |
| 6 hours | 105.2 ± 20.9 | 111.4 ± 21.3 | 0.53 |
| 10 hours | 157.1 ± 35.0 | 150.6 ± 31.2 | 0.65 |
| 24 hours | 303.6 ± 108.1 | 407.4 ± 450.2 | 0.43 |
| 5 μg/mL CRP | | | |
| 6 hours | 442.3 ± 85.6 | 417.4 ± 72.7 | 0.69 |
| 10 hours | 1,291.0 ± 229.4 | 1,458.9 ± 227.6 | 0.31 |
| 24 hours | 3,187.5 ± 652.3 | 3,083.0 ± 629.1 | 0.65 |
| 1 μg/mL LPS | | | |
| 6 hours | 530.3 ± 101.6 | 502.4 ± 97.0 | 0.87 |
| 10 hours | 759.0 ± 441.6 | 750.7 ± 471.1 | 0.73 |
| 24 hours | 1,139.0 ± 879.4 | 899.4 ± 884.1 | 0.10 |

Values are mean SEM from 15 experiments performed in duplicates. The net production of MCP-1 was calculated by subtracting the concentration without stimulus from those induced by LPS or recombinant CRP. Wilcoxon signed rank test was applied for statistical analysis.
physiological milieu. An advantage of the ex vivo whole blood cytokine stimulation technique is that it provides a composite measure of response that can involve several different cell types activated in a biologically relevant environment.

Using concentrations of homocysteine that had inflammatory effects in vitro, and are in the range that may occur in patients with hyperhomocysteinemia [41], we found no effect on IL-6 or MCP-1 production in whole blood over 24 hours of incubation. This contrasts with responses in human aortic endothelial cells where responses to homocysteine occurred rapidly, plateauning within 2–8 hours, and were inhibited by cycloheximide indicating that de novo protein synthesis had occurred [7]. A possible explanation for the different findings may be that the whole blood environment provides antioxidant defenses that are not present in cell culture and may thus attenuate the pro-inflammatory effects of homocysteine that are thought to be mediated by free radicals [42]. Thus, our findings suggest that the previous observations that homocysteine stimulated the production of cytokines in isolated cells in vitro may not be generalizable to the in vivo situation.

A limitation of this study is that we did not investigate the effect of escalating doses of pravastatin. Several randomized trials have shown that pravastatin 40 mg daily reduced CRP concentrations significantly [12,13,43], but there is no dose-response information for this response. Therefore, we chose a dose of pravastatin 40 mg daily as most likely to show an effect. Future studies could define the dose-response more completely.

In summary, human recombinant CRP with low concentrations of endotoxin stimulated the production of the proatherogenic mediators MCP-1 and IL-6 in human whole blood, but homocysteine did not. CRP-stimulated production of IL-6, but not MCP-1, was modestly attenuated by short-term treatment with pravastatin indicating that treatment with a statin may have rapidly anti-inflammatory actions in vivo and that these effects may be specific to particular cytokines and stimuli.

Acknowledgements

This work was supported by grants HL04012, HL65082, GM 31304, and GM 5MO1-RR00095 from the National Institutes of Health; Dr. Asanuma was supported by Merck Sharp and Dohme Foundation International Fellowship in Clinical Pharmacology and by the Japan Research Foundation for Clinical Pharmacology.

Corresponding Author: Yu Asanuma, MD, PhD, Division of Rheumatology and Applied Immunology, Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Moroyama-machi, irumagun, Saitama 350-0495, Japan. Tel: +81-49-276-1462; Fax: +81-49-295-4849; E-mail: yu2asa@saitama-med.ac.jp

Conflict of Interest: None declared.

References

1. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517–27.
2. Ridker PM. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet 2001;358:946–8.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–9.
4. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–43.
5. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877–81.
6. De Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002;54:599–618.
7. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: Implications for vascular disease. Circulation 2001;103:2717–23.
8. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531–4.
9. Ma PT, Gil G, Sudhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986;83:8370–4.
10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–9.
11 Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21:1712–9.
12 Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103: 1933–5.
13 Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344:1959–65.
14 Ferro D, Parrotto S, Basili S, Alessandri C, Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427–31.
15 Hedman M, Neuvonen PJ, Neuvonen M, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clin Pharmacol Ther 2003; 74:178–85.
16 Stein CM, Sadique AJ, Murray JJ, Wandel C, Kim RB, Wood AJ. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clin Pharmacol Ther 2001;69:317–23.
17 Rosenson RS, Tängey CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999;353:983–4.
18 Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med 1987;111:265–9.
19 Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992;4:361–8.
20 Pue CA, Mortensen RF, Marsh CB, Pope HA, Wewers MD. Acute phase levels of C-reactive protein enhance IL-1 beta and IL-1ra production by human blood monocytes but inhibit IL-1 beta and IL-1ra production by alveolar macrophages. J Immunol 1996;156:1594–600.
21 Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890–6.
22 Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, RebuZZi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417–24.
23 Havercate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and DisABilities Angina Pectoris Study Group. Lancet 1997;349:462–6.
24 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102: 2165–8.
25 Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999;19: 2364–7.
26 Rus HG, Vlaicu R, Nculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996; 127:263–71.
27 Goto T, Eden S, Nordenstam G, Sundh V, Svanborg-Eden C, Mattsby-Baltzer I. Endotoxin levels in sera of elderly individuals. Clin Diagn Lab Immunol 1994;1:684–8.
28 Wiedermann CJ, Kiechl S, Dunzendorfer S, Schätzberger P, Egger G, Oberhollenzer F, Willeit J. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: Prospective results from the Bruneck Study. J Am Coll Cardiol 1999;34:1975–81.
29 Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, Muggeo M, Xu Q, Wick G, Poewe W, Willeit J. Chronic infections and the risk of carotid atherosclerosis: Prospective results from a large population study. Circulation 2001;103:1064–70.
30 Eggesbo JB, Hjermann I, Hostmark AT, Kierulf P. LPS induced release of IL-1 beta, IL-6, IL-8 and TNF-alpha in EDTA or heparin anticoagulated whole blood from persons with high or low levels of serum HDL. Cytokine 1996;8:152–60.
31 Rezaie-Majd A, Maca T, Bueck RA, Valent P, Muller MR, Hustlein P, Kashanipour A, Minar E, Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002;22:1194–9.
32 Rosenson RS, Tängey CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999;353:983–4.
33 Kothe H, Dalhoff K, Rupp J, Müller A, Kreuzer J, Maass M, Katus HA. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniæ. Circulation 2000;101:1760–3.
34 Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol 2000;410:83–92.
35 Plenge JK, Hernandez TL, Weil KM, Poirier P, Gruñwald GK, Marcovina SM, Eckel RH. Simvastatin lowers C-reactive protein within 14 days; An effect independent of low-density lipoprotein.
cholesterol reduction. Circulation 2002;106:1447–52.

36 Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-term simvastatin treatment. Circulation 2002;106:1211–8.

37 Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127–37.

38 Cohick CB, Furst DE, Quagliata S, Corcoran KA, Steere KJ, Yager JG, Lindsley HB. Analysis of elevated serum interleukin-6 levels in rheumatoid arthritis: Correlation with erythrocyte sedimentation rate or C-reactive protein. J Lab Clin Med 1994;123:721–7.

39 Woodward M, Rumley A, Lowe GD, Tunstall-Pedoe H. C-reactive protein: Associations with hematologocal variables, cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 2003;122:135–41.

40 Hedman M, Neuvonen PJ, Neuvonen M, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clin Pharmacol Ther 2003;74:178–85.

41 Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042–50.

42 Wang G, Karmin O. Homocysteine stimulates the expression of monocyte chemoattractant protein-1 receptor (CCR2) in human monocytes: Possible involvement of oxygen free radicals. Biochem J 2001;357:233–40.

43 Albert MA, Danielson R, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001;286:64–70.